MedPath

A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma

Phase 3
Conditions
Sarcoma, Kaposi
HIV Infections
Registration Number
NCT00002318
Lead Sponsor
Sequus Pharmaceuticals
Brief Summary

To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy ABV: Adriamycin (doxorubicin)/bleomycin/vincristine. To evaluate the safety and tolerance of DOX-SL compared to ABV in a population of AIDS patients with severe KS.

Detailed Description

Patients are randomized to receive either DOX-SL or the ABV combination. Infusions are given on day 1 and every 2 weeks for a total of six cycles. Kaposi's sarcoma lesions are evaluated prior to every cycle, at the end of the last treatment cycle, and 4 weeks following the end of the last treatment. Patients must agree to have one or more representative KS lesions biopsied.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
225
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (26)

Dr Mahmoud Mustafa

🇺🇸

Washington, District of Columbia, United States

Baylor College of Medicine

🇺🇸

Houston, Texas, United States

East Bay AIDS Ctr

🇺🇸

Berkeley, California, United States

Apogee Med Group

🇺🇸

San Diego, California, United States

UCSF

🇺🇸

San Francisco, California, United States

Rush Presbyterian Med College

🇺🇸

Chicago, Illinois, United States

Henry Ford Hosp

🇺🇸

Detroit, Michigan, United States

Comprehensive Care Ctr

🇺🇸

Dallas, Texas, United States

Kaiser Permanente Med Ctr

🇺🇸

San Francisco, California, United States

Univ of Miami School of Medicine

🇺🇸

Miami, Florida, United States

American Med Research Institute

🇺🇸

Atlanta, Georgia, United States

Washington Univ

🇺🇸

St Louis, Missouri, United States

Dr Becky Miller

🇺🇸

Los Angeles, California, United States

Pacific Oaks Med Group

🇺🇸

Sherman Oaks, California, United States

New York Univ Med Ctr

🇺🇸

New York, New York, United States

Roswell Park Cancer Institute

🇺🇸

Buffalo, New York, United States

Infectious Disease Rsch Consortium of GA / SE Clin Resources

🇺🇸

Atlanta, Georgia, United States

Northwestern Med Faculty Foundation

🇺🇸

Chicago, Illinois, United States

Graduate Hosp / Tuttleman Cancer Ctr

🇺🇸

Philadelphia, Pennsylvania, United States

Saint Luke's - Roosevelt Hosp Ctr

🇺🇸

New York, New York, United States

Hematology - Oncology Med Group of San Fernando Valley

🇺🇸

Encino, California, United States

UCSF - San Francisco Gen Hosp

🇺🇸

San Francisco, California, United States

San Francisco Veterans Administration Med Ctr

🇺🇸

San Francisco, California, United States

Illinois Masonic Med Ctr / The Cancer Ctr

🇺🇸

Chicago, Illinois, United States

H Lee Moffit Cancer Ctr and Research Institute

🇺🇸

Tampa, Florida, United States

Saint Vincent's Hosp and Med Ctr

🇺🇸

New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath